Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer

Kyla N. Velaer, Ryan L. Steinberg, Lewis J. Thomas, Michael A. O’Donnell, Kenneth G. Nepple

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Patients with high-grade muscle invasive bladder cancer (NMIBC) receive intravesical therapy with bacillus Calmette-Guérin (BCG) as the well-established standard-of-care. However, even with prompt induction of intravesical therapy, approximately 40 % of patients will recur within 2 years. For patients who fail BCG, options include radical cystectomy, repeat BCG therapy, or alternative intravesical salvage therapy. In this review, we will discuss the most recent published evidence on salvage intravesical therapy with an emphasis on a more in-depth report of our therapeutic strategy with sequential gemcitabine and docetaxel intravesical therapy for this treatment-refractory population. In addition, we will provide practical advice on our approach to this challenging patient population including the use of operative staging to aid early identification of treatment failures.

Original languageEnglish
Article number38
JournalCurrent urology reports
Volume17
Issue number5
DOIs
StatePublished - May 1 2016

Keywords

  • Bacillus Calmette-Guérin
  • Docetaxel
  • Gemcitabine
  • Mycobacterium bovis
  • Urinary bladder neoplasms

Fingerprint

Dive into the research topics of 'Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer'. Together they form a unique fingerprint.

Cite this